Vincerx Pharma

Oqory's TROP2 ADC, OQY-3258, Shows Promise in Breast Cancer Trials; Vincerx Merger Proposed

- Oqory's anti-TROP2 ADC, OQY-3258, demonstrates promising Phase 1a/1b results in solid tumors, particularly in breast cancer subtypes, showcasing high overall response rates. - In previously untreated triple-negative breast cancer, OQY-3258 achieved an 80% confirmed overall response rate, with median duration of response and progression-free survival not yet reached. - OQY-3258 exhibits a favorable safety profile compared to other TROP2 ADCs, with minimal Grade ≥3 adverse events and no reported cases of interstitial lung disease or severe rash. - Vincerx Pharma and Oqory, Inc. propose a strategic merger to advance OQY-3258 into global Phase 3 trials and develop a differentiated ADC pipeline, pending customary closing conditions.